Loading organizations...
BioPacificVentures operates as a venture capital firm, concentrating its investments on innovative companies within the life sciences, food and agriculture technology, and high-tech sectors. The firm typically engages in Series A and Series B funding rounds, applying a focused approach to support the development and growth of its portfolio companies. It seeks to identify and back ventures with significant potential across its specialized industries.
The firm was co-founded in 2005 by Andrew Kelly, Patrick Coyle, and Bill Kermode, primarily establishing its presence in Auckland, New Zealand. Andrew Kelly, with a PhD and broad experience spanning food, agriculture, and health and wellness, played a key role in founding the firm. Their insight stemmed from recognizing a need for a specialist venture fund dedicated to these critical sectors within the Australia and New Zealand regions.
BioPacificVentures directs its investments towards companies based in the United States, New Zealand, and Australia, aiming for successful outcomes through IPOs or acquisitions. The firm’s vision is to cultivate strong innovation ecosystems within its target markets and specialized sectors. It strives to propel the advancement of transformative technologies that address significant market opportunities.
BioPacificVentures has 2 tracked investments across 1 company. The latest tracked deal is $20.0M Series B in Ocunexus Therapeutics in July 2012.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jul 1, 2012 | Ocunexus Therapeutics | $20.0M Series B | — | Domain Associates, Kleiner Perkins, Versant Ventures, GBS Venture Partners, Rusnanomedinvest |
| Apr 1, 2011 | Ocunexus Therapeutics | $19.0M Series B | — | Domain Associates, Kleiner Perkins, Versant Ventures, GBS Venture Partners |
